Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cost keeps many diabetics from taking needed insulin

The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.

Read More »

Novartis’ SMA Gene Therapy On Fast Track For Approval

Novartis’ gene therapy treatment for spinal muscular atrophy could receive marketing approval as early as May 2019 after the U.S. Food and Drug Administration granted AVXS-101, now dubbed Zolgensma, priority review.

Read More »

Express Scripts offers new formulary for lower list-price drugs

Express Scripts Holding Co. announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients.

Read More »

Coherus prices biosimilar to Amgen’s Neulasta at 33 percent discount

Coherus BioSciences Inc. will price the company’s biosimilar to Amgen Inc.’s infection-fighting treatment Neulasta at a 33 percent discount.

Read More »

FDA Proposes Steps to Standardize Generic Drugs Globally

U.S. Food and Drug Administration Commissioner Scott Gottlieb announced that the regulatory agency is relaunching the Drug Competition Action Plan in 2019 with some additional initiatives.

Read More »

Trump Signs FTC Law That Allows for Biosimilar Scrutiny

President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.

Read More »

Study Shows Drugs on FDA Shortage List Are Likely to See Price Hikes

According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.

Read More »

Why Does Immunotherapy Cost So Much?

Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.

Read More »

PTC’s SMA drug shows promise in two studies

PTC Therapeutics announced interim data from part 1 of the company’s open-label clinical trials of risdiplam (RG7916) for Type 1, 2 and 3 spinal muscular atrophy (SMA).

Read More »

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA’s skin cancer drug Libtayo, made in partnership with Regeneron Pharmaceuticals Inc., was approved by the U.S. Food and Drug Administration.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom